Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells - Takeaways - MDSpire

Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells

  • By

  • Susan Gellert

  • Bastian Kruse

  • Johannes Peters

  • Susanne Bonifatius

  • Thomas Tüting

  • Anthony C. Buzzai

  • June 22, 2026

  • 0 min

Share

  • 1

    Genetic mutations disrupting interferon signaling allow tumor cells to evade immune checkpoint inhibitor therapy.

  • 2

    Oncolytic virotherapy can specifically target and eliminate IFN-unresponsive tumor cell subclones.

  • 3

    Natural Killer cells eliminate IFN-unresponsive subclones in mixed tumor cell transplants due to low MHC-I expression.

  • 4

    Following immunotherapy, dedifferentiated IFN-responsive tumor cells can re-emerge, resisting both immune and viral control.

  • 5

    The findings highlight the dual role of cancer cell-intrinsic IFN signaling in tumor resistance mechanisms.

Original Source(s)

Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells

  • by Susan Gellert, Bastian Kruse, Johannes Peters, Susanne Bonifatius, Thomas Tüting, Anthony C. Buzzai

  • June 22, 2026

Related Content

Case Report: Exchange transfusion for hemolytic anemia and acute kidney injury associated with hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin in a patient with hepatocellular carcinoma

A screening model for advanced colorectal neoplasia based on tumor markers and inflammatory indices: a retrospective study with an online risk calculator

Antibody-drug conjugates in colorectal cancer: current landscape and future perspectives from clinical trials